Melanom: A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma

Stadium/Indikation inkl. Kurzinfo

Melanom – 2nd line

Stadium III oder IV
BRAF oder NRAS mutiert

panRAF Inhibitor + ERK Inhibitor oder MEK Inhibitor oder CDK4 and CDK6 Inhibitor

Kurztitel

Novartis CLXH254C12201
NCT04417621

Offizieller Titel

A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma

Behandelnder Fachbereich